Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
thats ino
its very possible this program awards a grant to inovio they have kept a good relationship with the government..outside of that its just speculation but it is bullish for the sector
I hear what your saying mackwheaton and agree biotech investing is met with many challenges r&d cost,competitors,securing funding and unstable markets..securing funding from big pharma,governments or academic institutions is no easy task and with out that inovio shares will be constantly diluted and the technology would be sold off for cheap to fund the clinical trials process the company is undergoing. Inovio's financial stability lays solely on securing large partnerships. A large pharmaceutical company partnership would be a great boost for ino and possibly help secure future deals with other companies. Anyone pumping that ino doesn't need to partner or ino is going to 100 dollars should hold that mindset for several years, because maybe one day that might be the case..here's an example taken from Inovio's 10-q released may 31st 2013 "the NIAID and VGX Int'l accounted for approximately 69% and 14%, of our consolidated revenue in 2012"..securing funding accounts for a lot concerning ino lets hope the management team is successful in their search of a partner.
Broad Agency Announcement for the Advanced Development of Medical Countermeasures for Pandemic Influenza
Synopsis:
Added: Jul 16, 2013 1:48 pm
A Broad Agency Announcement (BAA) will be issued that sets forth advanced development areas of interest for the Influenza Division of the Office of the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services.
BARDA is the lead Federal agency for the advanced development of medical countermeasures (MCM) to protect the United States against public health emergency threats, including chemical, biological, radiological and nuclear agents, emerging infectious diseases, and pandemic influenza.
The Pandemic and All Hazard Preparedness Act, Pub. L. No. 109-417, 42 U.S.C. § 241 et seq. (PAHPA; http://www.gpo.gov/fdsys/pkg/PLAW-109publ417/pdf/PLAW-109publ417.pdf) and The Pandemic and All Hazard Preparedness Reauthorization Act, Pub. L. No. 113-5, (PAHPRA; http://www.gpo.gov/fdsys/pkg/PLAW-113publ5/pdf/PLAW-113publ5.pdf) direct BARDA to promote (i) innovations in technologies that may assist MCM advanced research and development, (ii) research and development of tools, devices, and technologies, and (iii) research to promote strategic initiatives, such as rapid diagnostics, broad spectrum antimicrobials, and vaccine manufacturing technologies.
BARDA's Influenza Division seeks the advanced research and development of MCMs to protect the civilian population of the United States against pandemic influenza, and anticipates that research and development activities awarded under the BAA will serve to advance the knowledge and scientific understanding of candidate MCMs toward licensure or approval by the Food and Drug Administration.
The priorities of the BARDA Influenza Division are closely aligned with the National Strategy for Pandemic Influenza (November 2005), the National Pandemic Influenza Implementation Plan (May 2005), The Public Health Emergency Medical Countermeasures Enterprise Review (August 2010), the President's Council of Advisors on Science and Technology report on influenza vaccine manufacturing (August 2010), and the BARDA Strategic Plan 2011-2016 (October 2011).
Influenza Areas of Interest
The BAA will seek white papers that focus on one or more of the following areas of interest, which will be further described in Part I of the BAA.
1. Personal Protective Equipment (Masks and Respirators) for Influenza Infection & All-
Hazards
2. Full-Featured Continuous Ventilators for Influenza Infection and All-Hazards
3. Clinical Influenza Test Systems and Diagnostic Tools
4. Influenza Therapeutics
5. Influenza Vaccines
6. Influenza Vaccine Manufacturing Improvement
The BAA will be issued under sections 6.102(d)(2) and 35.016 of the Federal Acquisition Regulation, and submissions selected for award will result from full and open competition in compliance with The Competition in Contracting Act of 1984, Pub. L. No. 98-369, as amended.
This synopsis is not a BAA; the BAA is anticipated to be posted on or about July 31, 2013. The BAA's open period will be identified in the BAA itself. The BAA will be open to all responsible sources regardless of business size. Multiple awards may be made under the BAA.
(My opinion on this announcement)
This announcement makes Inovio's bioterrorism work uniquely poised to gain funding and resources through this initiative. Robin Robinson Director for Biomedical Advanced Research and Development Authority was a featured presenter at the Infectious Diseases World Summit 2013 july 8th and David Weiner hosted a segment called "New Vaccines & Future Trends in Vaccine Development" and also "Novel Technologies in Vaccine Development".. Michele A. Kutzler a member of David Weiners lab personnel also presented data on DNA Vaccines for Prevention of Clostridium Difficile-associated Disease using inovios cellecta device.
Here are some statements made by Inovio's managment this year from PR's.
(Apr 10, 2013) Inovio is collaborating with Dr. Connie Schmaljohn, Chief Scientist at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). The goal of this public/private partnership is to develop a device that would facilitate rapid vaccination of U.S. troops stationed around the world against multiple infectious diseases and protect civilian populations from pandemic threats.
Dr. J. Joseph Kim, Inovio's president & CEO, said, "This new device would provide a means to rapidly and painlessly deliver multiple vaccines simultaneously to large groups of people. This collaboration builds on Inovio's strong relationship with Dr. Schmaljohn and her team at USAMRIID in which Inovio is bringing medical innovation to several biodefense efforts. Moreover, the advancements from this project will enable rapid and efficient delivery of Inovio's SynCon® vaccines for universal flu, HIV, and other infectious diseases on a mass scale."
pr released April 20, 2013 on Inovio's universal H1N1 flu vaccine
"We are advancing the development of a universal seasonal flu vaccine to protect against H1N1, H3N2, and Type B influenza strains, the subtypes comprising today's FDA-approved seasonal vaccines. In addition to the ongoing H1N1 study in elderly subjects (65+ years), for which we reported positive interim data in December, the company is completing immunogenicity testing across multiple strains in animal models of its vaccine constructs for A/H3N2 and Type B influenza.
We are also advancing development initiatives focused on the pandemic influenza subtypes H5N1 and H7N9. Our goal is to access the pandemic stockpiling market, which is dominated by government buyers.Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases."
If you fully read the Broad Agency Announcement preview then read what Inovio is working towards you'll know why this bullish for them. Also this synopsis is not a BAA the BAA is anticipated to be posted on or about July 31, 2013. I would follow up on that.
Intimately involved with the principals lol
Tempered by the number of DNA vaccines ? DNA vaccines are just now starting to show the amount of immune responses needed to be clincally significant to make it to market, this has been triggered by improvements in the delivery technology thats why big pharma has been acquiring companies associated with this new generation of DNA vaccines to suggest there is a cap on that holds no weight. When personal computers came out people thought there was no way every could afford to own and it wouldn't be accessible people put a cap on how profitable a computer company can be..the fact was an industry was being revolutionized much like medicine is going through now..you know the rest of the story anyways if 1 of 11 clinical trials actually have a decent chance of making it to market then Inos pipeline might be one of the safest bet.
chm_760 Vaccines (ISSN 2076-393X), an international open access journal, is published by MDPI online quarterly.
newest abstract link http://www.mdpi.com/2076-393X/1/3/262
This new by the way check post below
Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation
Kathleen A. Cashman 1,* email, Kate E. Broderick 2 email, Eric R. Wilkinson 1 email, Carl I. Shaia 3 email, Todd M. Bell 3 email, Amy C. Shurtleff 4 email, Kristin W. Spik 1 email, Catherine V. Badger 1 email, Mary C. Guttieri 1,†email, Niranjan Y. Sardesai 2 email and Connie S. Schmaljohn 5
1 Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA
2 Inovio Pharmaceuticals, Inc., Blue Bell, PA 19422, USA
3 Pathology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA
4 Integrated Toxicology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA
5 Office of the Chief Scientists, Headquarters, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA
†Present address: Metabiota, 1410 Q Street NW, Suite 300, Washington, DC 20009, USA
* Author to whom correspondence should be addressed.
Received: 31 May 2013; in revised form: 8 July 2013 / Accepted: 10 July 2013 / Published: 18 July 2013
Abstract: Lassa virus (LASV) causes a severe, often fatal, hemorrhagic fever endemic to West Africa. Presently, there are no FDA-licensed medical countermeasures for this disease. In a pilot study, we constructed a DNA vaccine (pLASV-GPC) that expressed the LASV glycoprotein precursor gene (GPC). This plasmid was used to vaccinate guinea pigs (GPs) using intramuscular electroporation as the delivery platform. Vaccinated GPs were protected from lethal infection (5/6) with LASV compared to the controls. However, vaccinated GPs experienced transient viremia after challenge, although lower than the mock-vaccinated controls. In a follow-on study, we developed a new device that allowed for both the vaccine and electroporation pulse to be delivered to the dermis. We also codon-optimized the GPC sequence of the vaccine to enhance expression in GPs. Together, these innovations resulted in enhanced efficacy of the vaccine. Unlike the pilot study where neutralizing titers were not detected until after virus challenge, modest neutralizing titers were detected in guinea pigs before challenge, with escalating titers detected after challenge. The vaccinated GPs were never ill and were not viremic at any timepoint. The combination of the codon-optimized vaccine and dermal electroporation delivery is a worthy candidate for further development.
Ino 1400 will target breast and lung cancer..then be tested as a universal cancer vaccine
I feel for you man, your really confused
I was able to view full study from this link I would post it but it is very long. This was a very lengthy and impressive study.
Acknowledgments:
This work was supported in part by NIH grants and a grant from the Basser Research Center awarded to
DBW.
http://cancerimmunolres.aacrjournals.org/content/early/2013/07/17/2326-6066.CIR-13-0001.full.pdf+html
good find looks like this is the study people are waiting for
Thanks man
i understood exactly what you were saying and answered your question in a few different ways, i hope you have some clarity on the topic at hand now
ok your question was "So your saying inovio and invivo are affiliated somehow?" who said that and how does it in anyway apply to the study i posted
when medical journals or biotech studies use the word In Vivo that means inside the body..what you did is combine that term into one word and that lead you to a company called invivo...also (ep) is used to describe electroporation
"In vivo EP-mediated delivery" are you you didnt read that and assume In vivo some how transalted into the company Invivo do you know what in vivo means? do you what ep means?
monymony..i see you posted the a link by tammol32 on the website science alerts, but if you go the medical journal is was submitted for publication you will see the article became available online july 15th hope that helps you
Journal of Vascular Surgery Received 15 January 2013; accepted 17 April 2013. published online 15 July 2013.
http://www.jvascsurg.org/inpress
monomoney looks like you read only half the abstract so i dont really know if we can have a conversation on it till your done with that, this has no affiliation to nviv,...fsa also if you could scroll down the original post you'll see the affiliations..upenn...David Weiner...so monomey your convinced their using some other persons electroporation device thats interesting just highly unlikely giving the source and people involved in the study
ya those translations were horrible, but it was taken directly from vgx website maybe will here a more detailed English version
2013-07-15 pr from vgx website
Inter VGX "universal flu prevention DNA vaccines popular"
the United States funded research is being developed in collaboration with Inovio universal flu prevention practices and clinical studies of a DNA vaccine of swine H7N9 avian influenza virus DNA vaccine presented the results of non-clinical studies revealed that the 15 days .
This announcement swine flu influenza pan-Buddha Agency and the Asia-Pacific region consisting of experts organized by the non-profit organization APACI 2013 TEPIK / APACI took place at the International Symposium on Influenza.
Universal influenza DNA vaccines, Inovio in charge of the Amir Khan, Ph.D., director of product development, the new universal flu vaccine in the session's preventive DNA vaccine development strategies, and extensive cross-prevention phase 1 clinical studies have shown an ability announced. Another recent trend in China, the new bird flu H7N9 DNA vaccine derived and non-clinical studies were published.
Chinese Center for Disease Control, Dr. belong Luzhao Feng influenza epidemiology and diagnosis occurred in the session since February this year the status of H7N9 bird flu patients, treatment, etc., and the countermeasures described in China. Yet China's new bird flu this fall occurs again about paying attention, he added.
Domestic and international experts who participated in the symposium and Inno Inter VGX non Oga joint research and development on a universal influenza DNA vaccine that expressed great interest is a legend. H7N9 avian flu viruses, especially new fans demik prevention sinkeon noted for excellence in DNA vaccines.
Inter president bakyounggeun VGX "domestic concerns, as well as all over the world, and a big new fan demik strain induced by the following countries to prepare for a crisis, swine flu, bird flu DNA vaccines universal DNA vaccine research and development," said "The excellence through ongoing clinical research continues to prove out," he said
study released today David Weiner Journal of Vascular Surgery
CELLECTRA device worth a ton if success in trials continue(EP)is expanding its medical use
(published online 15 July 2013)
In vivo electroporation of constitutively expressed HIF-1a plasmid DNA improves neovascularization in a mouse model of limb ischemia
Objective
Hypoxia-inducible factor-1 alpha (HIF-1a) is a transcription factor that stimulates angiogenesis during tissue ischemia. In vivo electroporation (EP) enhances tissue DNA transfection. We hypothesized that in vivo EP of plasmid DNA encoding a constitutively expressed HIF-1a gene enhances neovascularization compared with intramuscular (IM) injection alone.
Methods
Left femoral artery ligation was performed in mice assigned to three groups: (1) HIF-EP (n = 13); (2) HIF-IM (n = 14); and (3) empty plasmid (pVAX)-EP (n = 12). A single dose of HIF-1a or pVAX DNA (20 µL of 5 µg/µL each) was injected into the ischemic adductor muscle followed by EP (groups one and three). Mice in group two received IM injection of HIF-1a plasmid DNA alone. From preligation to days 0, 3, 7, 14, and 21 postligation, limb perfusion recovery quantified by laser Doppler perfusion imager, limb function, and limb necrosis were measured. On day 21, the surviving mice (4-5 per group) were sacrificed and adductor muscle tissues stained for necrosis using hematoxylin and eosin, capillary density (anti-CD31 antibodies), and collateral vessels via anti-a-smooth muscle actin antibodies.
Results
In vivo EP of HIF-1a DNA significantly improved limb perfusion (HIF-EP: 1.03 ± 0.15 vs HIF-IM: 0.78 ± 0.064; P < .05, vs pVAX-EP: 0.41 ± 0.019; P < .001), limb functional recovery (HIF-EP: 3.5 ± 0.58 vs HIF-IM, 2.4 ± 1.14; P < .05, vs pVAX-EP: 2.4 ± 1.14; P < .001), and limb autoamputation on day 21 (HIF-EP: 77% ± 12% vs HIF-IM: 43% ± 14%; P < .05 vs pVAX-EP: 17% ± 11%; P < .01). Adductor muscle tissue necrosis decreased (HIF-EP: 20.7% ± 1.75% vs HIF-IM: 44% ± 3.73; P < .001, vs pVAX-EP: 60.05% ± 2.17%; P < .0001), capillary density increased (HIF-EP: 96.83 ± 5.72 vessels/high-powered field [hpf] vs HIF-IM: 62.87 ± 2.0 vessels/hpf; P < .001, vs pVAX-EP: 39.37 ± 2.76 vessels/hpf; P < .0001), collateral vessel formation increased (HI-EP: 76.33 ± 1.94 vessels/hpf vs HIF-IM: 37.5 ± 1.56 vessels/hpf; P < .0001, vs pVAX-EP: 18.5 ± 1.34 vessels/hpf; P < .00001), and the vessels were larger (HIF-EP: 15,521.67 ± 1298.16 µm² vs HIF-IM: 7788.87 ± 392.04 µm²; P < .001 vs pVAX-EP: 4640.25 ± 614.01 µm²; P < .0001).
Conclusions
In vivo EP-mediated delivery of HIF-1a plasmid DNA improves neovascularization in a mouse model of limb ischemia and is a potentially suitable nonviral, noninvasive intervention to facilitate therapeutic angiogenesis in critical limb ischemia.
Clinical Relevance
There is an unmet therapeutic goal in the treatment of critical limb ischemia (CLI). Various clinical trials have applied therapeutic angiogenesis to induce neovascularization in CLI by administering proangiogenic cytokines, their associated genes, or cells. However, the results have shown limited efficacy. One of the limiting factors in this strategy is the lack of a targeted gene delivery method that introduces the gene encoding the cytokine of interest in a specific vascular bed – a delivery modality that is noninvasive, nonviral-based, and is associated with few side effects. Using a mouse model of limb ischemia, we report that in vivo electroporation of hypoxia-inducible factor-1 alpha plasmid DNA enhances neovascularization and that this modality may be applied as a noninvasive, nonviral, and targeted gene delivery method in the treatment of CLI.
AFFILIATIONS
Department of Medicine, Cardiovascular Division, Vascular Medicine Section, Perelman School of Medicine at the University of Pennsylvania and University of Pennsylvania Health System, Philadelphia, Pa
This work was supported by the National Institutes of Health through National Heart Lung and Blood Institute grant K12 HL083772-01. In addition to funding research experiments, this grant supported the salaries of Drs Ouma and Mohler.
Author conflict of interest: Dr Weiner has grant funding, participates in industry collaborations, has received speaking honoraria, and fees for consulting. This service includes serving on scientific review committees and advisory boards. Remuneration includes direct payments or stock options and in the interest of disclosure therefore he notes potential conflicts associated with this work with Pfizer, Bristol Myers Squibb, Inovio, Merck, VGXI, Aldevron, and possibly others. Licensing of technology from his laboratory has created over 100 jobs in the private sector in the biotech/pharma industry. The rest of the remaining authors have no conflicts of interest.
The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.
peer review
Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery
J Infect Dis. (2013)
doi: 10.1093/infdis/jit236
First published online: July 8, 2013
Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery
J Infect Dis. first published online July 8, 2013
July 9th Michele A. Kutzler inovio collaborator will present data
4:15 A New Fight against an Old Bug: Toxin RBD-based DNA Vaccines for Prevention of Clostridium Difficile-associated Disease
We created highly optimized plasmids encoding the receptor binding domain (RBD) from TcdA and TcdB where any putative N-linked glycosylation sites were altered. C57BL/6 mice and rhesus macaques were immunized intramuscularly 3 times with both plasmids, 2 weeks apart, followed by in vivo electroporation (Inovio Pharmaceuticals Cellectra).
• Discussion of the required host immune responses necessary for successful defense against infection and recurrence of disease
• Presentation of current pipeline immunotherapies for prevention of Clostridium difficile associated disease
• Highlight of the design and preclinical immunogenicity and efficacy testing of a novel highly optimized DNA-based vaccine encoding the RBD of Clostridium difficile toxins A and B
7–10 October 2013 The annual AIDS Vaccine conference Barcelona, Spain
conference description
Progress, Partnership and Perseverance. The annual AIDS Vaccine conference is the largest and most diverse international meeting of researchers, advocates, clinicians, private sector partners and public health experts working collaboratively to advance HIV vaccine science. HIV vaccine research has progressed further and faster in the last few years than at any time since the epidemic began. AIDS Vaccine 2013 will focus on partnerships and perseverance to transform these advances into a safe and effective vaccine to help end the pandemic.
Poster 288639 PENNVAX-B DNA Vaccine via Electroporation Drives Potent Cellular Immune Responses and Synthesis of Granzyme B, Perforin: Data from 3 Clinical Trials
can someone please explain to me the importance of Thursday ? what is the possible positives of this date thanks guys
what is best or worst case scenario for fnma & fmcc in this fed mtg today ? or is this mtg being over hyped
OneMedForum 2013 New York June 26th and 27th
OneMedForumNY 2013, June 26th-27th at the Metropolitan Club in New York City, will feature over 40 private and public companies with sector-altering technology and a growing reputation. Technologies at the benchtop level will present alongside revenue-positive market-stage companies.
Inovio listed as a presenting company
The Forum will also have ‘live’ webcast public and private company presentations
Can someone post link to a site showing where fmcc is trading in foreign markets
chart showing pending breakout..boom
its showing last trade 3.00 on investor hub..is this a t trade thats meaningless?
ya its about time
anyone notice the change in ownership forms posted a few mins ago then taken down
Conference this week
1 [153] Elucidating the Expression Kinetics and Infiltration Resulting from Gene Delivery Enhanced by Dermal Electroporation
Authors: Janess M. Mendoza, Gleb Kichaev, Dinah Amante, Christine Knott, Trevor R. F. Smith, Niranjan Y. Sardesai, Kate E. Broderick
Date/Time: Thursday, May 16, 2013 - 4:00 PM
Session Info: Poster Session: Physical Methods of Delivery (4:00 PM-6:00 PM)
2 [9] Enhanced DNA Vaccination Against a Tyrosinase (Tyr) Mediates Protection and Targets Myeloid-Derived Suppressor Cells in a Syngeneic Murine Model
Authors: Taron C. Gorham, Lavanya Mahadevan, Colleen Lucke, Randolph Lyde, Kenneth E. Ugen, Niranjan Y. Sardesai, Joseph J. Kim, Karuppiah Muthumani, David B. Weiner
Date/Time: Wednesday, May 15, 2013 - 3:15 PM
Session Info: Simultaneous Oral Abstract Sessions: Cancer - Immunotherapy I (3:15 PM-5:15 PM)
3 [341] Minimally Invasive Electroporation of Synthetic DNA Vaccines for the Induction CTL and Functional Humoral Immune Responses Against HIV
Authors: Megan Wise, Karuppiah Muthumani, Kate E. Broderick, Amir S. Khan, Janess Mendoza, Maria Yang, Jian Yan, Natalie Hutnick, Niranjan Y. Sardesai, David B. Weiner
Date/Time: Friday, May 17, 2013 - 5:30 PM
Session Info: Poster Session: DNA Vectorology & Gene Targeting I (5:30 PM-7:30 PM)
4 [397] IL-12 Increases Immune Responses Induced by a Novel pDNA Prostate Cancer Immunotherapy Approach in Non-Human Primates
Authors: Bernadette Ferraro, Amritha Balakrishnan, Jewell N. Walters, Devin J. Myles, Jian Yan, Amir S. Khan, Niranjan Y. Sardesai, David B. Weiner
Date/Time: Friday, May 17, 2013 - 5:30 PM
Session Info: Poster Session: Cancer - Immunotherapy II (5:30 PM-7:30 PM)
5 [45] Inducing Humoral and Cellular Responses to Multiple Sporozoite and Liver-Stage Malaria Antigens Using pDNA
Authors: Bernadette Ferraro, Kendra T. Talbot, Amritha Balakrishnan, Matthew P Morrow, Natalie A. Hutnick, Devin J. Myles, Devon J. Shedlock, Nyamekye Obeng-Adjei, Jian Yan, Rachel Shiver, Amir S. Khan, Maria Yang, Ami S. Brown, Ulrike Wille-Reece, Ashley Birkett, Niranjan Y. Sardesai, David B. Weiner
Date/Time: Wednesday, May 15, 2013 - 3:15 PM
Session Info: Simultaneous Oral Abstract Sessions: Infectious Diseases and Vaccines (3:15 PM-4:15 PM)
341] Minimally Invasive Electroporation of Synthetic DNA Vaccines for the Induction CTL and Functional Humoral Immune Responses Against HIV
Megan Wise, Karuppiah Muthumani, Kate E. Broderick, Amir S. Khan, Janess Mendoza, Maria Yang, Jian Yan, Natalie Hutnick, Niranjan Y. Sardesai, David B. Weiner. University of Pennsylvania, Philadelphia, PA; Inovio, Blue Bell, PA
It is important to develop new approaches to HIV that generate both Functional antibody responses as well as CTL capable of killing diverse viruses. We have recently reported strong T cell and antibody responses induced in a humans using a synthetic HPV DNA vaccine delivered by a highly efficient EP (Bagarazzi et al STM 2012). Furthermore, in a study with the HVTN, recent clinical data from the HIV Vaccine Trials Network, HVTN-080 reported that CELLECTRA®-5P intramuscular electroporation (EP) of our synthetic Clade B consensus DNA HIV antigens (Env, Gag, and Pol) along with the plasmid adjuvant IL-12 generated strong antigen-specific cellular immune responses in humans resulting in a 90% response rate (Kalams et al 2013 MS in review). Here we build on these results by development of minimally invasive EP delivery technologies (MID-EP) to target the dermal tissue and by improved plasmid construct design of a collection of synthetic Consensus and center of tree (COT) immunogens. We report the ability of these approaches to generate strong binding, ADCC activity and neutralizing antibody (Ab) responses in guinea pigs, and rabbits as well as in preliminary NHP studies. We observed induction of invivo CTL/killing activity against 20 diverse HIV viruses including primary HIV isolates induced by the vaccine using a novel invivo killing assay. Furthermore we observe NAb titers engendered by immunization against a panel of 15 Tier-1 HIV viruses from Clades A-D in the range of 20 -200 in the Tzm-Bl neutralization assay. The magnitude of the humoral response was boosted to 20-1000 range using a MID-EP DNA prime-protein boost regimen. Our results suggest that study of construct design and selection by minimally invasive electroporation devices appears to be a relevant strategy for HIV DNA vaccinations in a prophylactic model targeting HIV. Combined with the design of novel HIV consensus based Env antigens these DNA-EP combination vaccines should be further investigated and have important implications for DNA vaccine candidates targeting HIV and other difficult pathogens.
Keywords: Non-Viral Gene Delivery; Vaccines; Synthetic Gene Delivery Systems
Session: Poster Session: DNA Vectorology & Gene Targeting I (5:30 PM-7:30 PM)
Date/Time: Friday, May 17, 2013 - 5:30 PM
Room: Exhibit Hall C/D
i think your right only a few weeks left in the 2nd qtr, i was fully convinced HIV publication would already be out, but management has habit of being off on their timelines. Inovio requires some patience though im glad to see your still invested, 2nd half of the year should be generous to investors with our cash run away and catalyst heading up to cervical cancer results which will be huge if positive